John Williamson
Psychiatric/Mental Health · Westerville, OHNPI 1740847946
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,775 of the $50,966 with a category attached, or 76.1%. AbbVie accounts for 81.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $27,298 and has fallen 62.0% since, to $10,370 in 2025. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $254.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- Axsome Therapeutics, Inc.$7K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$646
- Alkermes, Inc.$530
- Otsuka America Pharmaceutical, Inc.$243
- Indivior Inc.$132
- plus $271 from 6 others
What the payments were for
- Consulting fees$5,37511%
- Speaking & faculty fees$38,77576%
- Travel & lodging$2,4825%
- Food & beverage$4,1998%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 119 | $41,692 |
| Axsome Therapeutics, Inc. | 26 | $7,451 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $646 |
| Alkermes, Inc. | 15 | $530 |
| Otsuka America Pharmaceutical, Inc. | 8 | $243 |
| Indivior Inc. | 4 | $132 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Hikma Pharmaceuticals USA | 3 | $63 |
| Lundbeck LLC | 3 | $43 |
| Braeburn Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,966 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $9,723 |
| Atomoxetine Hcl | 11 | $856 |
| Gabapentin | 15 | $167 |
| Bupropion Hcl SrBupropion Hcl | 16 | $109 |
| Trazodone Hcl | 19 | $37 |
| Escitalopram Oxalate | 16 | $28 |
| Clonidine Hcl | 13 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $63 | $9,72346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Westerville
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.